Cargando…
Angiotensin II Receptor Blockers and Cancer Risk: A Meta-Analysis of Randomized Controlled Trials
Angiotensin II receptor blockers (ARB) are widely used drugs that are proven to reduce cardiovascular disease events; however, several recent meta-analyses yielded conflicting conclusions regarding the relationship between ARB and cancer incidence, especially when ARB are combined with angiotensin-c...
Autores principales: | Zhao, Yun-Tao, Li, Peng-Yang, Zhang, Jian-Qiang, Wang, Lei, Yi, Zhong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4863811/ https://www.ncbi.nlm.nih.gov/pubmed/27149494 http://dx.doi.org/10.1097/MD.0000000000003600 |
Ejemplares similares
-
Angiotensin-Receptor Blocker, Angiotensin-Converting Enzyme Inhibitor, and Risks of Atrial Fibrillation: A Nationwide Cohort Study
por: Hsieh, Yu-Cheng, et al.
Publicado: (2016) -
Comparison of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular outcomes in hypertensive patients with type 2 diabetes mellitus: A PRISMA-compliant systematic review and meta-analysis
por: lv, Xiaodan, et al.
Publicado: (2018) -
Assessment of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker on the split renal function in the patients with primary hypertension
por: Zhang, Jingsi, et al.
Publicado: (2021) -
Clinic and Home Blood Pressure Lowering Effect of an Angiotensin Receptor Blocker, Fimasartan, in Postmenopausal Women with Hypertension
por: Kim, Song-Yi, et al.
Publicado: (2016) -
The Prognostic Role of Angiotensin II Type 1 Receptor Autoantibody in Non-Gravid Hypertension and Pre-eclampsia: A Meta-analysis and Our Studies
por: Lei, Jinghui, et al.
Publicado: (2016)